Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.

Autor: Davar D; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: davard@upmc.edu., Morrison RM; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA., Dzutsev AK; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Karunamurthy A; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA., Chauvin JM; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Amatore F; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Deutsch JS; Division of Dermatopathology, Johns Hopkins University, Baltimore, MD, USA., Das Neves RX; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Rodrigues RR; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA; Genetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., McCulloch JA; Genetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Wang H; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Hartman DJ; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA., Badger JH; Genetics and Microbiome Core, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Fernandes MR; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Bai Y; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Sun J; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA; Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA., Cole AM; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Aggarwal P; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Fang JR; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA., Deitrick C; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Bao R; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Duvvuri U; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA., Sridharan SS; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA., Kim SW; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA., A Choudry H; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA., Holtzman MP; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA., Pingpank JF; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA., O'Toole JP; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Division of Plastic Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA., DeBlasio R; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Jin Y; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Ding Q; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Gao W; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Groetsch C; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Pagliano O; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Rose A; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Urban C; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA., Singh J; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA., Divarkar P; Nanostring Technologies, Seattle, WA, USA., Mauro D; Checkmate Pharmaceuticals, Cambridge, MA, USA., Bobilev D; Checkmate Pharmaceuticals, Cambridge, MA, USA., Wooldridge J; Checkmate Pharmaceuticals, Cambridge, MA, USA., Krieg AM; Checkmate Pharmaceuticals, Cambridge, MA, USA., Fury MG; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Whiteaker JR; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Zhao L; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Paulovich AG; Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Najjar YG; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Luke JJ; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Kirkwood JM; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA., Taube JM; Division of Dermatopathology, Johns Hopkins University, Baltimore, MD, USA; Tumor Microenvironment Core, Bloomberg-Kimmel Institute of Immunotherapy, Mark Foundation Center for Advanced Imaging and Genomics, Johns Hopkins University, Baltimore, MD, USA., Park HJ; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA., Trinchieri G; Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: trinchig@mail.nih.gov., Zarour HM; Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA; University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA; Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, USA; Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: zarourhm@upmc.edu.

Publikováno v: Cancer cell [Cancer Cell] 2024 Oct 30. Date of Electronic Publication: 2024 Oct 30.